Yali Dou, Ph.D

Professor, Pathology
Professor, Biological Chemistry

5215 Med Sci I

1301 Catherine St

Ann Arbor, MI  48109-5602

 

(734) 615-1315

Areas of Interest

Cell fate decisions are controlled by tissue-specific transcription factors acting in concert with epigenetic regulators such as enzymes that carry out histone post-translational modifications. Epigenetic dysregulation emerges as a key characteristic of human malignancies. The Dou lab seeks to determine the epigenetic basis of normal and aberrant embryonic and hematopoietic development. By comparing the ontogeny of gene regulatory networks in embryonic stem cells as well as leukemia stem cells, the lab aims to understand how lineage-specifying transcription factors, non-coding DNA regulatory regions and epigenetic modulating enzymes cooperate to maintain or reprogram stem cell characteristics, expand differentiation potentials, and perturb disease development. These studies promise to not only advance our understanding of the context-specific roles of epigenetic modulators in development and diseases, but also provide critical insights into designing novel target-based therapeutic strategies in cancer treatment and regenerative medicine.

Honors & Awards

2014  Basic Science Research Award, University of Michigan Medical School
2012  Scholar Award, Leukemia & Lymphoma Society
2011  Innovative Research Grant, Stand Up To Cancer
2010  Gertrude B. Elion Cancer Research Award, American Association for Cancer Research
2010  Research Scholar Grant, American Cancer Society
2006  Biological Sciences Scholar, University of Michigan

Published Articles or Reviews

Recent Publications

Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF.
Zhang Y, Jang Y, Lee JE, Ahn J, Xu L, Holden MR, Cornett EM, Krajewski K, Klein BJ, Wang SP, Dou Y, Roeder RG, Strahl BD, Rothbart SB, Shi X, Ge K, Kutateladze TG.
Nat Commun. 2019; 10: 2314.

Modulating Protein-Protein Interactions with Visible-Light-Responsive Peptide Backbone Photoswitches.
Albert L, Peñalver A, Djokovic N, Werel L, Hoffarth M, Ruzic D, Xu J, Essen LO, Nikolic K, Dou Y, Vázquez O.
Chembiochem. 2019; 20: 1417-29.

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.
Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL.
Cancer Cell. 2018; 34: 643-58.

Re-SET for Transcription.
Liu Y, Dou Y.
Mol Cell. 2018; 70: 985-6.

Effects of histone H2B ubiquitylation on the nucleosome structure and dynamics.
Krajewski WA, Li J, Dou Y.
Nucleic Acids Res. 2018; 46: 7631-42.

HuR regulates telomerase activity through TERC methylation.
Tang H, Wang H, Cheng X, Fan X, Yang F, Zhang M, Chen Y, Tian Y, Liu C, Shao D, Jiang B, Dou Y, Cong Y, Xing J, Zhang X, Yi X, Songyang Z, Ma W, Zhao Y, Wang X, Ma J, Gorospe M, Ju Z, Wang W.
Nat Commun. 2018; 9: 2213.

Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis.
Zhang H, Zhou B, Qin S, Xu J, Harding R, Tempel W, Nayak V, Li Y, Loppnau P, Dou Y, Min J.
Genes Dev. 2018; 32: 341-6.

Phosphoproteomics links glycogen synthase kinase-3 to RNA splicing.
Khoa LTP, Dou Y.
J Biol Chem. 2017; 292: 18256-57.

For a list of publications from Michigan Research Experts, click HERE